芬妥木單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | IGF-1受體 |
| 臨床資料 | |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 943453-46-1  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6462H9948N1736O2020S54 |
| 摩爾質量 | 146,008.04 g·mol−1 |
芬妥木單抗（INN：Figitumumab；開發代號：CP-751871）是一種針對胰島素樣生長因子1受體的單株抗體，[1]已被研究用於治療多種癌症，例如腎上腺皮質癌[2]和非小細胞肺癌。[3]
這種藥物由輝瑞公司開發，但他們於2011年1月停止了該藥物的開發並停止了生產。[4]
臨床試驗
第一個III期試驗（針對非小細胞肺癌）因死亡人數過多而於2009年12月暫停，[5]但其他試驗仍在繼續。[6][7]
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.
- ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology. March 2010, 65 (4): 765–73. PMC 2875253
. PMID 19649631. doi:10.1007/s00280-009-1083-9.
- ^ Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clinical Lung Cancer. July 2009, 10 (4): 273–80. PMID 19632947. doi:10.3816/CLC.2009.n.038.
- ^ Cancer sufferer fears future without 'life-saver' drug. BBC News. July 2014 [2024-01-22]. （原始內容存檔於2015-09-25）.
- ^ Krauskopf L. Pfizer ends late-stage lung-cancer study. Reuters. 29 December 2009 [2024-01-22]. （原始內容存檔於2010-02-26）.
- ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
- ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
- ^ Breast cancer study aims to speed drugs, cooperation. Reuters. March 2010 [2024-01-22]. （原始內容存檔於2010-03-22）.
| |||||||||||||||||||||||||||||||||||||||